THC:NYE-Tenet Healthcare Corporation (USD)

EQUITY | Medical Care Facilities | New York Stock Exchange

Last Closing

USD 105.11

Change

+0.24 (+0.23)%

Market Cap

USD 1.59B

Volume

0.89M

Analyst Target

USD 30.18
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tenet Healthcare Corp is a health care services company. The Company, together with its subsidiaries, operates healthcare delivery networks in urban and suburban markets in the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
HCA HCA Holdings Inc

N/A

USD 80.70B
UHS Universal Health Services Inc

N/A

USD 11.68B
DVA DaVita HealthCare Partners Inc

N/A

USD 11.67B
FMS Fresenius Medical Care Corpora..

N/A

USD 11.00B
CHE Chemed Corp

N/A

USD 9.53B
EHC Encompass Health Corp

N/A

USD 8.26B
SEM Select Medical Holdings

N/A

USD 3.87B
AMN AMN Healthcare Services Inc

N/A

USD 2.16B
AGL agilon health Inc

N/A

USD 2.06B
USPH US Physicalrapy Inc

N/A

USD 1.60B

ETFs Containing THC

AZTD Aztlan Global Stock Selec.. 4.21 % 0.00 %

N/A

USD 0.04B
PTH Invesco DWA Healthcare Mo.. 3.12 % 0.60 %

N/A

USD 0.13B
GVIP Goldman Sachs Hedge Indus.. 2.31 % 0.45 %

N/A

USD 0.17B
HLTH:AU VanEck Global Healthcare .. 2.13 % 0.00 %

N/A

USD 0.06B
NHYB:CA NBI High Yield Bond ETF 1.05 % 0.00 %

N/A

CAD 1.07B
IVOV Vanguard S&P Mid-Cap 400 .. 0.82 % 0.20 %

N/A

USD 0.83B
JNKS:LSE SSgA SPDR ETFs Europe I p.. 0.66 % 0.00 %

N/A

USD 0.14B
SJNK:LSE SSgA SPDR ETFs Europe I p.. 0.58 % 0.00 %

N/A

USD 0.15B
ISCV iShares Morningstar Small.. 0.46 % 0.00 %

N/A

USD 0.40B
BSJN 0.00 % 0.42 %

N/A

N/A
HYG iShares iBoxx $ High Yiel.. 0.00 % 0.49 %

N/A

USD 16.19B
HYND 0.00 % 0.48 %

N/A

N/A
IJJ iShares S&P Mid-Cap 400 V.. 0.00 % 0.25 %

N/A

USD 7.64B
JKL 0.00 % 0.30 %

N/A

N/A
MDYV SPDR® S&P 400 Mid Cap Va.. 0.00 % 0.15 %

N/A

USD 2.45B
SHYL Xtrackers Short Duration .. 0.00 % 0.20 %

N/A

USD 0.10B
HYDW Xtrackers Low Beta High Y.. 0.00 % 0.25 %

N/A

USD 0.21B
HYUP Xtrackers High Beta High .. 0.00 % 0.35 %

N/A

USD 0.01B
BSJQ Invesco BulletShares 2026.. 0.00 % 0.42 %

N/A

USD 0.50B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

N/A

USD 17.08B
SHYG iShares 0-5 Year High Yie.. 0.00 % 0.30 %

N/A

USD 5.78B
SJB ProShares Short High Yiel.. 0.00 % 0.95 %

N/A

USD 0.10B
HYLB Xtrackers USD High Yield .. 0.00 % 0.20 %

N/A

USD 3.05B
HYLV 0.00 % 0.40 %

N/A

N/A
BSJR Invesco BulletShares 2027.. 0.00 % 0.00 %

N/A

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.09% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.09% 96% N/A 97% N/A
Trailing 12 Months  
Capital Gain 82.48% 87% B+ 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.48% 87% B+ 95% A
Trailing 5 Years  
Capital Gain 264.46% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 264.46% 100% F 95% A
Average Annual (5 Year Horizon)  
Capital Gain 48.62% 96% N/A 95% A
Dividend Return 48.62% 96% N/A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 82.65% 17% F 10% F
Risk Adjusted Return 58.83% 92% A 85% B
Market Capitalization 1.59B 83% B 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Care Facilities) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.51 63% 52%
Price/Book Ratio 5.86 29% 14%
Price / Cash Flow Ratio 3.97 70% 62%
Price/Free Cash Flow Ratio 6.85 70% 52%
Management Effectiveness  
Return on Equity 25.92% 86% 88%
Return on Invested Capital 12.92% 78% 74%
Return on Assets 6.29% 83% 79%
Debt to Equity Ratio 925.50% 11% 3%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector